TY - JOUR
T1 - Progress in the Management of Malignant Pleural Mesothelioma in 2017
AU - McCambridge, Amanda J.
AU - Napolitano, Andrea
AU - Mansfield, Aaron S.
AU - Fennell, Dean A.
AU - Sekido, Yoshitaka
AU - Nowak, Anna K.
AU - Reungwetwattana, Thanyanan
AU - Mao, Weimin
AU - Pass, Harvey I.
AU - Carbone, Michele
AU - Yang, Haining
AU - Peikert, Tobias
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.
AB - Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.
KW - BAP1
KW - Immunotherapy
KW - Mesothelin
KW - Mesothelioma
KW - Review
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85046378485&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2018.02.021
DO - 10.1016/j.jtho.2018.02.021
M3 - Review article
C2 - 29524617
AN - SCOPUS:85046378485
SN - 1556-0864
VL - 13
SP - 606
EP - 623
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 5
ER -